Literature DB >> 185114

Clinical correlations of serum proinsulin-like material in islet cell tumours.

R N Alsever, M R Stjernholm, K E Sussman, M E Mako, A H Rubenstein.   

Abstract

To examine the possibility that the concentration of circulating proinsulin-like material (PLM) might be helpful in evaluating the therapeutic response of patients with islet cell tumours, serum levels of PLM in three patients with islet cell tumours were correlated with hypoglycaemic symptoms and plasma glucose concentrations before and after treatment. In two patients ranges of fasting PLM concentration were 0.21-0.29 and 0.91-0.93 ng/ml, respectively, before treatment. After surgical excision of their islet cell adenomas, PLM concentrations decreased to 0.06-0.09 and 0.03-0.05 ng/ml. Insulin concentrations were low preoperatively in both patients and were unchanged postoperatively. The resulting relief from hypoglycaemia was paralleled by a reduction of PLM, with no significant change in insulin. In a third patient, treatment with streptozotocin resulted in marked symptomatic improvement, a 65% reduction in PLM concentration, but no significant change in insulin levels. Relapse was associated with increasing frequency of hypoglycaemic symptoms and increasing PLM concentrations. These findings suggest that changes in the levels of serum PLM may prove to be a sensitive indicator of the response of islet cell tumours to therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 185114     DOI: 10.1007/bf01219519

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Insulinoma with low circulating insulin levels: the diagnostic value of proinsulin measurements.

Authors:  R N Alsever; J P Roberts; J G Gerber; M E Mako; A H Rubenstein
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

2.  Plasma proinsulin in patients with functioning pancreatic islet cell tumors.

Authors:  B M Sherman; S Pek; S S Fajans; J C Floyd; J W Conn
Journal:  J Clin Endocrinol Metab       Date:  1972-08       Impact factor: 5.958

3.  Circulating proinsulin-like material in patients with functioning insulinomas.

Authors:  R A Gutman; N R Lazarus; J C Penhos; S Fajans; L Recant
Journal:  N Engl J Med       Date:  1971-05-06       Impact factor: 91.245

4.  Effect of streptozotocin on qualitative aspects of plasma insulin in a patient with a malignant islet cell tumor.

Authors:  W G Blackard; A R Garcia; C L Brown
Journal:  J Clin Endocrinol Metab       Date:  1970-08       Impact factor: 5.958

5.  Biological activity of proinsulin and related polypeptides in the fat tissue.

Authors:  S S Yu; A E Kitbachi
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

6.  Proinsulin and insulin release with a human insulinoma and adjacent nonadenomatous pancreas.

Authors:  R A Gutman; G Fink; J R Shapiro; H Selawry; L Recant
Journal:  J Clin Endocrinol Metab       Date:  1973-05       Impact factor: 5.958

7.  Human serum proinsulin.

Authors:  F Melani; A H Rubenstein; D F Steiner
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

8.  Metabolism of endogenous proinsulin and insulin in man.

Authors:  J I Starr; A H Rubenstein
Journal:  J Clin Endocrinol Metab       Date:  1974-02       Impact factor: 5.958

9.  Plasma insulin: fluctuations in the "big" insulin component in man after glucose and other stimuli.

Authors:  P Gorden; J Roth
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

10.  Proinsulin secretion by a pancreatic beta-cell adenoma. Proinsulin and C-peptide secretion.

Authors:  F Melani; W G Ryan; A H Rubenstein; D F Steiner
Journal:  N Engl J Med       Date:  1970-10-01       Impact factor: 91.245

View more
  1 in total

1.  Portal, hepatic and peripheral insulin immunoreactive substances before and after removal of an insulinoma.

Authors:  C Villaume; B Beck; J P Pointel; P Drouin; G Debry
Journal:  J Endocrinol Invest       Date:  1982 Sep-Oct       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.